Information Provided By:
Fly News Breaks for December 21, 2018
AIMT
Dec 21, 2018 | 17:21 EDT
Piper Jaffray analyst Christopher Raymond kept an Overweight rating and $60 price target on Aimmune Therapeutics following the AR101 BLA submission for peanut allergy in children and adolescents ages 4-17. The analyst said he expects "this BLA will not only be accepted but may also receive Priority Review, putting it on track for a late summer approval/launch" and believes "the FDA will like this one." Raymond continues to "view the set-up on this name as decidedly positive" and remains a buyer of Aimmune shares.
News For AIMT From the Last 2 Days
There are no results for your query AIMT